A web-based survey assessing the impact of storage flexibility on the daily life of patients and caregivers administering growth hormone

References

• Reiter EO, Price DA, Wilton P, et al. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: Analysis of a large international database. J Clin Endocrinol 2006;91(6):2047-54
   Web of Science ®Google Scholar
• Van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, et al. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 2003;88(3):1119-25
   PubMed Web of Science ®Google Scholar
• Van Pareren Y, Mulder P, Houdijk M, et al. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab 2003;88(8):3584-90
   PubMed Web of Science ®Google Scholar
• Cutfield WS, Derraik JG, Gunn AJ, et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS ONE 2011;6(1):e16223
   PubMed Web of Science ®Google Scholar
• Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: A systematic review. Horm Res Paediatr 2013;79(4):189-96
   PubMed Web of Science ®Google Scholar
• Kapoor RR, Burke SA, Sparrow SE, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child 2008;93(2):147-8
   PubMed Web of Science ®Google Scholar
• Aydın BK, Aycan Z, Şiklar Z, et al. Adherence to growth hormone therapy: results of a multicenter study. Endocr Pract 2014;20(1):46-51
   PubMed Web of Science ®Google Scholar
• Rosenfeld RG, Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 2008;14(2):143-54
   PubMedGoogle Scholar
• Haverkamp F, Gasteyger C. A review of biopsychosocial strategies to prevent and overcome early-recognized poor adherence in growth hormone therapy of children. J Med Econ 2011;14(4):448-57
   PubMedGoogle Scholar
• Kremidas D, Wisniewski T, Divino VM, et al. Administration burden associated with recombinant human growth hormone treatment: perspectives of patients and caregivers. J Pediatr Nurs 2013;28(1):55-63
   PubMed Web of Science ®Google Scholar
• Norditropin Prescribing Information. Available from: www.novo-pi.com/norditropin.pdf [Last accessed January 2015]
   Google Scholar
• Pleil AM, Kimel M, McCormack J et al. Psychometric assessment of the Injection Pen Assessment Questionnaire (IPAQ): measuring ease of use and preference with injection pens for human growth hormone. Health Qual Life Outcomes 2012;10:126
   PubMed Web of Science ®Google Scholar
• Nickman NA, Haak SW, Kim J. Cost minimization analysis of different growth hormone pen devices based on time-and-motion simulations. BMC Nurs 2010;9:6
   PubMedGoogle Scholar
• Hogan ME, van der Vaart S, Perampaladas K, et al. Systematic review and meta-analysis of the effect of warming local anesthetics on injection pain. Ann Emerg Med 2011;58(1):86-98
   PubMed Web of Science ®Google Scholar
• Kappelgaard A-M, Bojesen A-MSkydsgaard K, et al. Liquid growth hormone: preservatives and buffers. Horm Res 2004;62(Suppl 3):98-103
   PubMed Web of Science ®Google Scholar
• Laursen T, Hansen B, Fisker S. Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol Toxicol 2006;98(2):218-21
   PubMed Web of Science ®Google Scholar
• Dumas H, Panayiotopoulos P, Parker D, Pongpairochana V. Understanding and meeting the needs of those using growth hormone injection devices. BMC Endocr Disord 2006;6:5
   PubMedGoogle Scholar
• Fidotti E. A history of growth hormone injection devices. J Pediatr Endocrinol Metab 2001;14(5):497-501
   PubMed Web of Science ®Google Scholar
• Main KM, Jørgensen JT, Hertel NT, et al. Automatic needle insertion diminishes pain during growth hormone injection. Acta Paediatr 1995;84(3):331-4
   PubMed Web of Science ®Google Scholar
• Horne R, Weinman J, Barber N, et al. Concordance, adherence and compliance in medicine taking: A conceptual map and research priorities. National Institute for Health Research Service Delivery and Organisation R&D; London: 2006
   Google Scholar
• National Institute of Health and Clinical Evidence. Guidance on the use of human growth hormone (somatropin) in children with growth failure. Technology Appraisal Guide No. 188. 2010. Available from: http://publications.nice.org.uk/human-growth-hormone-somatropin-for-the-treatment-of-growth-failure-in-children-ta188 [Last accessed September 2014]
   Google Scholar
• Norgren S. Adherence remains a challenge for patients receiving growth hormone therapy. Pediatr Endocrinol Rev 2009;6:545-8
   PubMedGoogle Scholar
• Cutfield W, Lindberg A, Albertsson Wikland K, et al. Final height in idiopathic growth hormone deficiency: the KIGS experience. KIGS International Board. Acta Paediatr Suppl 1999;88:72-5
   PubMedGoogle Scholar
• Haverkamp F, Johansson L, Dumas H, et al. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Ther 2008;30:307-16
   PubMed Web of Science ®Google Scholar
• Pfützner A, Hartmann K, Winter F, et al. Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: a noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patients. Clin Ther 2010;32(11):1918-34
   PubMed Web of Science ®Google Scholar
• Rohrer TR, Winter F, Qvist M, Kappelgaard AM. Comparison of intuitiveness, ease of use and preference among three prefilled, disposable growth hormone injection pens. Expert Opin Drug Deliv 2013;10(12):1603-12
   PubMed Web of Science ®Google Scholar
• Van Dongen N, Kaptein AA. Parents’ views on growth hormone treatment for their children: psychosocial issues. Patient Prefer Adherence 2012;6:547-53
   PubMed Web of Science ®Google Scholar
• Meinhardt U, Eiholzer U, Seitz L, et al. Parent preference in Switzerland for easy-to-use attributes of growth hormone injection devices quantified by willingness to pay. Expert Rev Med Devices 2014;11(1):31-8
   PubMed Web of Science ®Google Scholar
• Wickramasuriya BP, Casey A, Akhtar S, et al. Factors determining patient choice of device for GH therapy. Horm Res 2006;65:18-22
   PubMed Web of Science ®Google Scholar
• Fuchs GS, Mikkelsen S, Knudsen TK, Kappelgaard AM. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test. Clin Ther 2009;31(12):2906-14
   PubMed Web of Science ®Google Scholar
• Kappelgaard AM, Mikkelsen S, Knudsen TK, Fuchs GS. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients. J Pediatr Endocrinol Metab 2011;24(7-8):489-96
   PubMed Web of Science ®Google Scholar
• Kappelgaard AM, Mikkelsen S, Bagger C, Fuchs GS. Children and adolescent acceptability of a new device system to administer human growth hormone–a pilot study. J Pediatr Endocrinol Metab 2012;25(3-4):285-94
   PubMed Web of Science ®Google Scholar
• Pleil AM, Darendeliler F, Dörr HG, et al. Results from an international multicenter trial evaluating the ease-of-use of and preference for a newly developed disposable injection pen for the treatment of growth hormone deficiency in treatment-naïve children and adults. Med Devices (Auckl) 2014;7:61-71
   PubMedGoogle Scholar
• Rapaport R, Saenger P, Schmidt H, et al. Validation and ease of use of a new pen device for self-administration of recombinant human growth hormone: results from a two-center usability study. Med Devices (Auckl) 2013;6:141-6
   PubMedGoogle Scholar
• Tauber M, Jaquet D, Jesuran-Perelroizen M, et al. User assessment of Norditropin NordiFlex®, a new prefilled growth hormone pen: a Phase IV multicenter prospective study. Patient Prefer Adherence 2013;7:455-62
   PubMed Web of Science ®Google Scholar
• Adachi M. Assessment of user-friendliness of the Norditropin FlexPro for pediatric patients treated with recombinant human growth hormone: results of an open-label user survey. J Pediatr Endocrinol Metab 2013;26(11-12):105-10
   PubMed Web of Science ®Google Scholar
• Oyarzabal M, Aliaga M, Chueca M, et al. Multicentre survey on compliance with growth hormone therapy: what can be improved? Acta Paediatr 1998;87(4):387-91
   PubMed Web of Science ®Google Scholar
• Stanhope R, Buchanan C, Butler G, et al. An open-label acceptability study of Norditropin SimpleXx-a new liquid growth hormone formulation. J Pediatr Endocrinol Metab 2001;14:735-40
   PubMed Web of Science ®Google Scholar
• Acerini C, Albanese A, Casey A, et al. Initiating growth hormone therapy for children and adolescents. Br J Nurs 2012;21(18):1091-7
   PubMedGoogle Scholar